Brineura
Brineura ingredients
| Active ingredient | Strength |
|---|---|
| Cerliponase alfa | see label |
What Brineura is used for
The FDA lists the approved uses on the official label (below). In the EU, cerliponase alfa is approved as Brineura for:
Brineura is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Brineura
- Generic name
- Cerliponase alfa
- Made by
- BioMarin Pharmaceutical Inc.
- Forms
- Kit
- FDA approval
- Biologic licence (BLA) BLA761052
- On the US market since
- 2017
Official information
- Brineura prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Cerliponase alfa)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Brineura?
Brineura (Cerliponase alfa) is a specialist medicine made by BioMarin Pharmaceutical Inc., approved by the US FDA.
What are the ingredients of Brineura?
Brineura contains Cerliponase alfa.
Is Brineura approved in Europe?
The same active substance is approved in the EU as Brineura.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA